Choo Chee Kong

SEC Form 4 insider trading activity

Choo Chee Kong has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Jul 25, 2026.

On the most recent filing, Choo Chee Kong is listed as Director, 10% Owner at CytoMed Therapeutics Ltd. Inside the rolling window, Choo Chee Kong reported 3 open-market purchases totaling $429K in GDTC and no open-market sales. The largest disclosed transaction in the window is a purchase of 100,000 GDTC shares on Jul 14, 2026, worth $150K.

Companies traded

Insider Buying

$429K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
GDTCPurchase$150KJul 25SEC ↗
GDTCPurchase$150KJul 25SEC ↗
GDTCPurchase$129KJun 15SEC ↗
Showing 1–3 of 3
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Choo Chee Kong made?

Choo Chee Kong has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.

Which companies does Choo Chee Kong trade?

Choo Chee Kong has filed SEC Form 4 disclosures for 1 company, including GDTC.

When was Choo Chee Kong's most recent SEC Form 4 filing?

Choo Chee Kong's most recent SEC Form 4 filing on Tracefour is dated Jul 25, 2026.

What is Choo Chee Kong's total buy and sell value in the current window?

Inside the rolling retention window, Choo Chee Kong bought $429K and sold $0 based on SEC Form 4 filings.

What was Choo Chee Kong's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 100,000 GDTC shares on 2026-07-14, worth $150K, per SEC Form 4 filings.